Evidence map›Paper›PMID 42410245›Full record

ArticleThe Journal of antibiotics2026

Tsukubacyclinone, a novel angucyclinone compound with anti-inflammatory activity in synovial cell line SW982, produced by Streptomyces sp. K21-0141.

Fumito Iizuka, Kentaro Uchida, Yuta Kikuchi, Yuta Awano, Miho Nagayoshi, Saki Ikeuchi, Kugo Takeda, Yoshihisa Ohashi, Gen Inoue, Tomoyasu Hirose and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fumito IizukaGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Kentaro UchidaDepartment of Orthopaedic Surgery, School of Medicine, Kitasato University, Sagamihara-shi, Kanagawa, Japan. kuchida@med.kitasato-u.ac.jp.
Yuta KikuchiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Yuta AwanoGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID http://orcid.org/0009-0005-1673-4994
Miho NagayoshiŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.
Saki IkeuchiMedical School, Okayama University, Okayama-shi, Okayama, Japan.
Kugo TakedaDepartment of Medical Engineering and Technology, Graduate School of Medical Sciences, Kitasato University, Sagamihara-shi, Kanagawa, Japan.
Yoshihisa OhashiDepartment of Orthopaedic Surgery, School of Medicine, Kitasato University, Sagamihara-shi, Kanagawa, Japan.
Gen InoueDepartment of Orthopaedic Surgery, School of Medicine, Kitasato University, Sagamihara-shi, Kanagawa, Japan.
Tomoyasu HiroseGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9463-8181
Yuki InahashiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan. y-ina@lisci.kitasato-u.ac.jp.ORCID http://orcid.org/0000-0001-7436-2037

Funding

Japan Agency for Medical Research and Development (AMED) JP22ama121035MEXT | Japan Society for the Promotion of Science (JSPS) 19H05685MEXT | Japan Society for the Promotion of Science (JSPS) JP23K08617MEXT | Japan Society for the Promotion of Science (JSPS) JP25K02765
6 · The paper itself

Abstract

Streptomyces species are prolific producers of structurally diverse secondary metabolites with a broad spectrum of biological activities. In this study, we isolated a novel angucyclinone compound, tsukubacyclinone (1), from the culture broth of Streptomyces sp. K21-0141. Tsukubacyclinone (1) exhibited potent anti-inflammatory effects in vitro. RNA sequencing of TNF-α-stimulated synovial cell line, SW982 revealed that tsukubacyclinone (1) downregulated pro-inflammatory genes, including IL1B and IL6, which was further validated by qPCR, without increasing LDH activity. KEGG pathway analysis indicated modulation of TNF, NF-κB, cytokine-cytokine receptor interaction, and JAK-STAT signaling. ELISA further confirmed a dose-dependent suppression of IL-1β and IL-6 protein. These findings suggest that tsukubacyclinone (1), as a novel angucyclinone-type compound, may target upstream cytokine signaling pathways to attenuate synovial inflammation, highlighting its potential as a disease-modifying agent for osteoarthritis and other chronic joint diseases. Future studies are warranted to investigate its in vivo pharmacological effects and molecular targets.

Indexed as

AnthraquinonesAnti-Inflammatory AgentsStreptomycesSynovial MembraneCell LineCytokinesHumansInterleukin-1betaInterleukin-6Signal TransductionTumor Necrosis Factor-alphaangucyclinoneAnthraquinonesAnti-Inflammatory AgentsCytokinesInterleukin-1betaInterleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID42410245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.